We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA placed valsartan manufacturer Zhejiang Huahai on an import alert and the EMA issued a noncompliance statement barring Europe’s drugmakers from using the company’s API in their blood pressure products. Read More
Keystone Laboratories of Memphis, Tennessee, was hit with a consent decree ordering the company to stop selling over-the-counter drugs until it complies with current manufacturing practice requirements. Read More
The FDA issued warning letters to four drugmakers over various CGMP violations at their facilities, some of which created risks of product contamination. Read More
The FDA slapped Watertown, Massachusetts, drug manufacturer pSivida with a Form 483 after inspectors found that the facility lacked defined procedures to ensure drug uniformity and homogeneity. Read More
The FDA hit Pompano Beach, Florida, compounder Vital Rx with a warning letter for manufacturing deficiencies that resulted in adulterated drug products and potential risks for patients. Read More
The FDA issued a warning letter to United Exchange, a Cerritos, California-based drug manufacturer for filing inaccurate ingredient information for the National Drug Code (NDC) directory. Read More